Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia

Clara Deambrogi, Lorenzo De Paoli, Marco Fangazio, Stefania Cresta, Silvia Rasi, Valeria Spina, Valter Gattei, Gianluca Gaidano, Davide Rossi

Research output: Contribution to journalArticlepeer-review

Abstract

The genetic profile of chronic lymphocytic leukemia (CLL) is characterized by a pool of recurrent lesions, including trisomy 12, deletions of 13q14, 11q22-q23, 17p13, and 6q21, and t(14)(q32) translocations [1]. The aforementioned lesions can be detected by FISH and may harbor prognostic information [1]. Array-based comparative genomic hybridization (aCGH) has identified gain of multiple regions on the short arm of chromosome 2 as a recurrent CLL lesion, that contain the REL, BCL11A, and MYCN proto-oncogenes that are involved in hematologic malignancies [2-5]. The exact prevalence of REL, BCL11A, and MYCN gains at the time of CLL diagnosis is currently unknown in consecutive series of the disease. Moreover, some studies indicate that 2p gains as a whole may herald progressive and/or poor risk disease, yet the prognostic contribution of the individual genes included in the amplicon, i.e., REL, BCL11A, and MYCN, remains undefined [4-6]. The aim of this study was twofold: (i) characterize the prevalence of REL, BCL11A, and MYCN gains in a consecutive CLL series at the time of diagnosis; (ii) define the prognostic relevance of REL, BCL11A, and MYCN gains in CLL.

Original languageEnglish
Pages (from-to)541-544
Number of pages4
JournalAmerican Journal of Hematology
Volume85
Issue number7
DOIs
Publication statusPublished - Jul 2010

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this